Press releases

28 December, 2018

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 28 December 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced an increase of the number of shares and votes in NeuroVive of 126,235 as a result of ...

11 December, 2018

Regulatory

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting, held at 1 pm on Thursday 17 January 2019 at Medicon Village, Scheelevägen ...

11 December, 2018

Regulatory

Correction to press release: “NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report”

Lund, Sweden, 11 December 2018 - NeuroVive Pharmaceutical AB(publ)("NeuroVive" or "the Company") announces adjustment of the following dates in the press release, published on December 10, 2018:

10 December, 2018

Regulatory

Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)

10 December, 2018

Regulatory

Outcome of the Exercise of Warrants in NeuroVive

Lund, Sweden, 10 December 2018 -NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announces the outcome of the exercise of warrants of serie ...

10 December, 2018

Regulatory

NeuroVive resolves on a Rights issue of MSEK 123.8 for continued drug development, and new publication date of the 2018 Year End Report

Lund, Sweden, 10 December 2018 - NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "t ...

22 November, 2018

Regulatory

NeuroVive Pharmaceutical AB Interim report January – September 2018

KL1333 approved for phase I clinical trial

15 November, 2018

Regulatory

NeuroVive receives Vinnova funding to support development of NV354, a novel treatment for genetic mitochondrial disorders

Lund, 15 November, 2018- NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awarded SEK 1.5 million as a first tranche of total SEK 5 million in ...

31 October, 2018

Regulatory

NeuroVive today announces that the subscription period for warrants of series 2018:1 will begin on Thursday, November 1

Lund, Sweden October 31 2018 - NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "the Company") (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces today that the subscription period for the warrants of ...

18 October, 2018

NeuroVive presents first preclinical NV354 efficacy results in a model for mitochondrial disease

Lund, Sweden, 18 October 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that positive experimental results for NV354, NeuroVive's preclinical lead candidate i ...

10 October, 2018

Regulatory

NeuroVive receives KL1333 clinical trial regulatory approval

Lund, Sweden, 10 October 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that it has received approval of its clinical trial application concerning a planned p ...

4 October, 2018

Regulatory

NeuroVive reports first NeuroSTAT clinical efficacy signal in TBI

Lund, Sweden, 4 October 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the successful completion of biomarker analyses of samples from its clinical study in se ...